Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
August 05 2020 - 9:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical
company committed to developing medicines that transform the lives
of people with rare neurological diseases, today announced that
Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will
participate in a panel discussion at the William Blair Biotech
Focus Conference 2020. The panel is titled, “New Therapies
Impacting the Epilepsy Treatment Landscape,” and will be held on
Thursday, August 6, 2020, at 12:00 p.m. ET.
A live audio webcast of the discussion can be
accessed through the Events & Presentations section of the
Company's website at investors.ovidrx.com. An archived replay of
the webcast will be available on the Company's website following
the live presentation.
About Ovid TherapeuticsOvid Therapeutics Inc.
is a New York-based biopharmaceutical company using its
BoldMedicine® approach to develop medicines that transform the
lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The Company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing OV935
(soticlestat) in collaboration with Takeda Pharmaceutical Company
Limited for the potential treatment of rare developmental and
epileptic encephalopathies (DEE). For more information on Ovid,
please visit www.ovidrx.com.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns McClellan,
Inc.sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman 1AB
katie@1abmedia.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024